Last updated: April 24, 2026
What Does CN111565761 Cover, and How Does It Sit in the China Drug Patent Landscape?
CN111565761 is a China patent publication with claim scope that is best assessed at the “what is claimed vs. what is disclosed” level: the operative claim coverage determines (1) whether it protects a specific active ingredient or (2) whether it protects formulation, process, polymorph/solid form, or method-of-use territory. Without the patent’s claim text and bibliographic section for CN111565761, a complete, accurate “scope and claims” analysis and a mapped landscape cannot be produced.
No structured claim-level or landscape conclusions are provided here.
What Is the Claimed Scope of CN111565761?
A claim-scope analysis requires the exact claim set (independent and dependent claims), including:
- Claim category (compound, composition, method-of-treatment, manufacturing process, solid form/polymorph, use claims)
- Defined subject matter (chemical structure identifiers, salt/ester/tautomer definitions, excipient lists, crystallinity/DSC/XRD markers)
- Functional language constraints (range limitations, “comprising” vs “consisting of,” parameter thresholds)
- Jurisdictional claim dependencies (which dependent claims are narrower)
No claim text is included in the input, so the claim boundaries cannot be rendered accurately.
What Is the Patent Status and Legal Posture for CN111565761?
A credible landscape needs the legal and procedural posture:
- Publication type (CN publication, PCT entry, divisional, continuation)
- Grant status and dates (grant, invalidation, active status)
- Whether claims were amended in prosecution
- Family members and counterpart jurisdictions (EP/US/WO)
No bibliographic or status data is provided in the input, so an authoritative status-based landscape cannot be constructed.
How Does CN111565761 Fit the China Landscape for the Same Drug Class?
A landscape requires at least:
- Identification of the drug substance or therapeutic target tied to CN111565761
- Mapping to other CN filings and grants around the same target (originator, generics, line extensions, new solid forms)
- Reference to Orange Book equivalents for China (when applicable) and major filing clusters
- Overlap analysis with likely citation families (prior art compounds, intermediate syntheses, formulation disclosures)
With no target/ingredient mapping in the input, the landscape cannot be built without introducing unsupported claims.
Where Does CN111565761 Likely Overlap: Composition, Solid Form, Process, or Use?
Landscape overlap depends on claim category. Common overlap patterns in China drug patents include:
- Compound patents: strong blocking against direct and sometimes design-around salts/polymorphs depending on definitions and claim construction
- Solid form patents: narrow but potent against specific crystalline forms and sometimes solvent-treated forms
- Process patents: protect manufacturing steps and can drive license needs if generic manufacturers use the same process
- Method-of-use patents: can still be circumvented by selecting different indications or dosing regimens depending on claim language
A precise call for CN111565761 needs the actual claim text and independent-claim structure.
What Would an Evidence-Based Claim-Chart Look Like for CN111565761?
A claim-chart requires:
- Each independent claim broken into elements
- Each dependent claim mapped as narrowing features
- Technical descriptors from the spec (examples, preparation, characterization)
- A “claim element vs. disclosure” matrix and “claim element vs. likely generic design-around” matrix
No patent text is present to enable this.
Key Takeaways
- CN111565761’s scope and claims cannot be analyzed accurately without the patent’s claim text and bibliographic/legal status.
- A China patent landscape placement requires knowing the claimed subject matter (ingredient/solid form/process/use) and the legal posture (grant and prosecution outcomes).
- No claim boundaries, overlap, or enforceability conclusions are provided for CN111565761 in the absence of the claim set and status data.
FAQs
-
Can a patent landscape be produced without CN111565761 claim text?
No. Claim-level mapping requires the exact independent and dependent claims and their parameter constraints.
-
What determines whether CN111565761 blocks generic entry in China?
The protected subject matter (compound/composition/solid form/process/use) and the claim definitions that generics would need to avoid.
-
What sources are typically used to build a China patent landscape for a specific drug?
CN patent family members, prosecution histories, citation networks, and status indicators for CN publications and grants.
-
How do dependent claims change practical risk in enforcement?
Dependent claims add specific narrowing features that can be avoided by design-arounds if those features are not met.
-
What is the fastest way to assess design-around freedom?
Identify the claim elements that are objectively testable (e.g., solid form characterization, process steps, explicit formulation components) and see which are easiest for a generic to change.
References
[1] CN111565761 (Chinese patent publication).
